Loading…
Employees: 511
Size Zhejiang Yatai Pharmaceutical (002370.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $514M, the 3799th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.60 on 6 Nov 2026.
Performance Over six months the shares fell 31.6%, against -17.3% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +11.6%); the operating margin is -10.8% (peer median 10.3%).
Valuation It trades at 9.8× enterprise value to sales against a peer median of 3.9× (5th most expensive of 19).
Capital Return on invested capital runs 6.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥313M | CN¥322M | CN¥403M | CN¥419M | CN¥372M |
| Revenue growth | — | -20% | -4% | +13% | — |
| Gross profit | CN¥121M | CN¥91.9M | CN¥109M | CN¥114M | CN¥113M |
| EBITDA | n/a | CN¥2.89M | CN¥27.4M | CN¥8.30M | CN¥7.13M |
| Net income | -CN¥15.1M | CN¥96.3M | CN¥34.2M | -CN¥11.9M | -CN¥133M |
| Free cash flow | -CN¥123M | CN¥27.1M | CN¥30.5M | CN¥9.23M | -CN¥3.87M |
| Capital expenditure | CN¥12.7M | CN¥5.05M | CN¥9.92M | CN¥7.46M | CN¥21.1M |
| Total debt | CN¥56.0M | CN¥60.3M | CN¥332M | CN¥692M | CN¥982M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002370.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -9.2% | 10th lowest of 21 |
| 6-month return | -31.6% | -17.3% | 6th lowest of 21 |
| Distance from 52-week high | -51.1% | -35.6% | 6th lowest of 21 |
| Revenue growth (TTM) | -4.1% | +11.6% | 4th lowest of 20 |
| Operating margin | -10.8% | 10.3% | 6th lowest of 19 |
| EV / Sales | 9.8× | 3.9× | 5th most expensive of 19 |
| ROIC minus cost of capital | -6.2 pp | -2.4 pp | 8th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |